Drug Trial Radar · NCT06468098
A Study of IBI363 in Subjects With Advanced Malignancies
Last checked: Nov 19, 2026Latest source record: Jul 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
556
Planned (sponsor's estimate)
Start
Jun 15, 2024
Primary completion
Jun 30, 2025
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter Phase Ib study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced malignancies patients
Conditions
- Advanced Malignancies
Interventions
IBI363 + chemotherapyDrug
In this group, patients will receive IBI363 and chemotherapy
IBI363 + Investigator's Choice SOCDrug
In this group, patients will receive IBI363 and Investigator's Choice SOC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Enent (AE)Time frame: Up to 90 days after the last administration
- Treatment-Emergent AE (TEAE)Time frame: Up to 90 days after the last administration
- Adverse Event of Special Interest (AESI)Time frame: Up to 90 days after the last administration
- Serious Adverse Event (SAE)Time frame: Up to 90 days after the last administration
- Objective response rate (ORR)Time frame: Through out the study (up to 2 years)
- disease control rate (DCR)Time frame: Through out the study (up to 2 years)
- time to response (TTR)Time frame: Through out the study (up to 2 years)
- duration of response (DoR)Time frame: Through out the study (up to 2 years)
- progression-free survival (PFS)Time frame: Through out the study (up to 2 years)
- Overall survival (OS)Time frame: Through out the study (an average of 2 years)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Chest Hospita
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.